SFM
TRIL

Signet Financial Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Signet Financial Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,058
Closed -$148K – 256
2020
Q4 		$148K Buy
+10,058
New +$145K 0.03% 226

Other funds holding TRIL

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Signet Financial Management's TRIL Position: Q1 2021 in Review

Signet Financial Management sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2021, closing a stake of 10,058 shares — an estimated $148K sold.

Signet Financial Management first reported a position in TRIL in Q4 2020 and held it in 1 quarter. The position peaked at $148K in Q4 2020. 125 funds tracked by Wall St. Rank hold TRIL as of Q1 2021.

  • Signet Financial Management reported no remaining Trillium Therapeutics Inc. position as of Q1 2021 after selling out during the quarter.
  • Signet Financial Management sold 10,058 Trillium Therapeutics Inc. shares in Q1 2021, an estimated $148K.
  • Signet Financial Management first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 1 quarter.
  • Signet Financial Management's Trillium Therapeutics Inc. position peaked at $148K in Q4 2020.
  • 125 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2021.

Based on Signet Financial Management's 13F filing for Q1 2021, filed 5 May 2021.